Bavarian Nordic presents new preclinical data for Covid-19 vaccine
Bavarian Nordic's first clinical studies with a vaccine for Covid-19 are almost ready. Ahead of launch, the firm has received a batch of positive preclinical data. This confirms the potential, according to Bavarian Nordic's CEO Paul Chaplin.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN
Bavarian Nordic is getting ready for its first in-human trial with the vaccine, which the firm in-licensed from Adaptvac, and now, in the first round, new data has arrived.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Biomarin awaits crucial approvals and flat growth in 2021
For subscribers
